Cardiovascular Systems Inc. (CSI) announced that it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) to market its Diamondback 360 Coronary Orbital Atherectomy System (OAS) as a treatment for severely calcified coronary arteries.

October 23, 2013 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced 15 trial results at VIVA 13. The trial results offered new information on advances in the treatment of vascular diseases.

Bracco Diagnostics Inc. announced the availability of syringe packs with spikes, to be used when loading contrast and saline for delivery with power injectors in computed tomography (CT) suites. Bracco syringe packs are specifically designed for use with the EmpowerCTA and Empower CT contrast delivery systems, offering greater flexibility in contrast and saline preparation. 

St. Jude Medical Inc. announced the U.S. Food and Drug Administration (FDA) approval and launch of its Ilumien Optis PCI optimization system, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease (CAD). The system will be on display for the first time in the United States during the 2013 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

October 22, 2013 — AtheroMed, a developer of catheter technologies for treating peripheral artery disease (PAD), announced results from its Endovascular Atherectomy Safety and Effectiveness (EASE) study during a late-breaking clinical trials session at the Vascular Interventional Advances (VIVA) 2013 conference in Las Vegas. Stephen Williams, M.D., director of the Vascular Medicine Center, Johns Hopkins University, presented the results of the study, which demonstrate the safety and effectiveness of the Phoenix atherectomy system in treating PAD.

A 56-year-old man who had a heart attack survived and is recovering at home after receiving two hours and forty-five minutes of cardiopulmonary resuscitation (CPR). The length of CPR time is believed to be among the longest on record and was made possible because of a mechanical chest compression machine called the Lucas device.

AngioScore Inc., a developer of angioplasty catheters for use in the treatment of cardiovascular disease, announced that preliminary data from the first-in-human (FIH) study (“Patent-C”) of the drug-coated AngioSculpt Scoring Balloon Catheter will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco the week of Oct. 28.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now